Posted on December 23rd, 2015
by Raphael Mannino
It is my great pleasure to introduce myself in my new role as Chief Technology Officer of Matinas BioPharma! For most of my career, I have been working on the development of the cochleate lipid-crystal nano-particle delivery technology as an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School. I am now very excited to be an integral part of the Matinas BioPharma team as we work to advance our orally-administered, encochleated broad spectrum fungicidal and broad spectrum aminoglycoside antibiotic drug formulations from clinical development toward commercialization to help treat patients with serious and life-threatening infections.
Cochleate technology promises to be the next generation lipid-based delivery technology, building on the older liposome technology. Liposomes were developed to create a more targeted drug delivery while reducing toxic side effects. Although liposomal delivery was an improvement, this technology has significant limitations and weaknesses. With our development of very small, solid, lipid-crystal particles, we have finally reached a point where the old promise of liposomes can be delivered! With anti-infectives, we have been able to demonstrate a targeted drug delivery to infected tissues, while significantly reducing the toxic side-effects of highly potent anti-infectives. Even better, the cochleate nano-particles are so small and stable that they can be swallowed and absorbed in the intestine. Thus, previously injectable-only medications can now be orally-administered.
We were proud to present the recent data from a preclinical study of MAT2203, an orally-administered, encochleated formulation of the broad spectrum antifungal medication amphotericin B, that demonstrated its potential to target and penetrate tissue at ICAAC/ICC 2015. For many decades, the oral delivery of anti-infectives has remained challenging, and injectable forms of most anti-infectives are still superior to oral pills or tablets. Recent clinical trial failures are a fresh reminder of this. We believe we have broken this paradigm with an oral cochleate form of amphotericin B (our MAT2203) by achieving the minimal concentrations in infected tissues two days earlier than the original injectable form of amphotericin B! We achieved this breakthrough in an animal model of invasive candidiasis, a highly lethal infection in which about one-third of patients do not survive.
We believe cochleate nano-crystal technology represents a breakthrough in anti-infective medicine development. As a member of the Matinas BioPharma team, I am looking forward to continuing my work and advancing our disruptive technology into clinical practice, hopefully providing safe, user- friendly, and effective life-saving benefit to many patients!
Raphael J. Mannino PhD, Chief Technology Officer at Matinas BioPharma
Click here for: MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection – Part 1 http://www.thechairmansblog.com/matinas-biopharma-holdings/roelof-rongen/mtnb-transforms-the-world-of-anti-infectives-oral-delivery-beats-injection-part-1/
Forward Looking Statements
Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect our business, particularly those identified in the risk factor and cautionary factors discussions in our SEC filings. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. We specifically disclaim obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.